Literature DB >> 24700273

Bioanalytical method validation: concepts, expectations and challenges in small molecule and macromolecule--a report of PITTCON 2013 symposium.

Edward D Bashaw1, Binodh DeSilva, Mark J Rose, Yow-Ming C Wang, Chinmay Shukla.   

Abstract

The concepts, importance, and implications of bioanalytical method validation has been discussed and debated for a long time. The recent high profile issues related to bioanalytical method validation at both Cetero Houston and former MDS Canada has brought this topic back in the limelight. Hence, a symposium on bioanalytical method validation with the aim of revisiting the building blocks as well as discussing the challenges and implications on the bioanalysis of both small molecules and macromolecules was featured at the PITTCON 2013 Conference and Expo. This symposium was cosponsored by the American Chemical Society (ACS)-Division of Analytical Chemistry and Analysis and Pharmaceutical Quality (APQ) Section of the American Association of Pharmaceutical Scientists (AAPS) and featured leading speakers from the Food & Drug Administration (FDA), academia, and industry. In this symposium, the speakers shared several unique examples, and this session also provided a platform to discuss the need for continuous vigilance of the bioanalytical methods during drug discovery and development. The purpose of this article is to provide a concise report on the materials that were presented.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24700273      PMCID: PMC4012041          DOI: 10.1208/s12248-014-9597-4

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  10 in total

1.  Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects.

Authors:  Yow-Ming C Wang; Wojciech Krzyzanski; Sameer Doshi; Jim J Xiao; Juan Jose Pérez-Ruixo; Andrew T Chow
Journal:  AAPS J       Date:  2010-10-21       Impact factor: 4.009

2.  Ligand-binding mass spectrometry to study biotransformation of fusion protein drugs and guide immunoassay development: strategic approach and application to peptibodies targeting the thrombopoietin receptor.

Authors:  Michael P Hall; Colin Gegg; Kenneth Walker; Christopher Spahr; Robert Ortiz; Vimal Patel; Steven Yu; Liana Zhang; Hsieng Lu; Binodh DeSilva; Jean W Lee
Journal:  AAPS J       Date:  2010-07-13       Impact factor: 4.009

Review 3.  How modeling and simulation have enhanced decision making in new drug development.

Authors:  Raymond Miller; Wayne Ewy; Brian W Corrigan; Daniele Ouellet; David Hermann; Kenneth G Kowalski; Peter Lockwood; Jeffrey R Koup; Sean Donevan; Ayman El-Kattan; Cheryl S W Li; John L Werth; Douglas E Feltner; Richard L Lalonde
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-11-07       Impact factor: 2.745

4.  Evaluation of a peptide ELISA for the detection of rituximab in serum.

Authors:  H Blasco; G Lalmanach; E Godat; M C Maurel; S Canepa; M Belghazi; G Paintaud; D Degenne; E Chatelut; G Cartron; C Le Guellec
Journal:  J Immunol Methods       Date:  2007-07-17       Impact factor: 2.303

5.  Incurred sample reanalysis.

Authors:  Brian Booth
Journal:  Bioanalysis       Date:  2011-05       Impact factor: 2.681

Review 6.  Learning versus confirming in clinical drug development.

Authors:  L B Sheiner
Journal:  Clin Pharmacol Ther       Date:  1997-03       Impact factor: 6.875

Review 7.  On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach.

Authors:  Guy M L Meno-Tetang; Philip J Lowe
Journal:  Basic Clin Pharmacol Toxicol       Date:  2005-03       Impact factor: 4.080

8.  Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE.

Authors:  Philip J Lowe; Didier Renard
Journal:  Br J Clin Pharmacol       Date:  2011-08       Impact factor: 4.335

9.  A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab.

Authors:  Naoto Hayashi; Yuko Tsukamoto; William M Sallas; Philip J Lowe
Journal:  Br J Clin Pharmacol       Date:  2006-11-10       Impact factor: 4.335

10.  The assay design used for measurement of therapeutic antibody concentrations can affect pharmacokinetic parameters: Case studies.

Authors:  Saloumeh K Fischer; Jihong Yang; Banmeet Anand; Kyra Cowan; Robert Hendricks; Jing Li; Gerald Nakamura; An Song
Journal:  MAbs       Date:  2012-07-23       Impact factor: 5.857

  10 in total
  1 in total

Review 1.  Evaluating and Reporting the Immunogenicity Impacts for Biological Products--a Clinical Pharmacology Perspective.

Authors:  Yow-Ming C Wang; Jie Wang; Yuen Yi Hon; Lin Zhou; Lanyan Fang; Hae Young Ahn
Journal:  AAPS J       Date:  2015-12-31       Impact factor: 4.009

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.